Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) James V. Freeman et al.   ANNALS OF INTERNAL MEDICINE

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) Amanda R. Harrington et al.   STROKE

Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin

(2012) Soyon Lee et al.  

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

(2012) Thomas Davidson et al.   EUROPEAN HEART JOURNAL

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

(2012) Anuraag R Kansal et al.   HEART

Is Dabigatran Cost Effective Compared With Warfarin for Stroke Prevention in Atrial Fibrillation?

(2012) Amelia K. Adcock et al.   NEUROLOGIST

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack

(2012) Hooman Kamel et al.   STROKE

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada

(2012) Michael Sharma et al.   THROMBOSIS AND HAEMOSTASIS

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials

(2012) Steve Deitelzweig et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark

(2012) Lars K Langkilde et al.   JOURNAL OF MEDICAL ECONOMICS

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

(2011) John A. Cairns et al.   CANADIAN JOURNAL OF CARDIOLOGY

Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation

(2011) Shimoli V. Shah et al.   CIRCULATION

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

(2011) Valentin Fuster et al.   CIRCULATION

2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)

(2011) L. Samuel Wann et al.   CIRCULATION

Durch Blutungen verursachte Kosten bei der Therapie des akuten Koronarsyndroms in Deutschland

(2011) Alexander Bufe et al.   HERZ

2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)

(2011) L. Samuel Wann et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

(2011) Anuraag Kansal et al.   THROMBOSIS AND HAEMOSTASIS

An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement

(2011) Corinne LeReun et al.   JOURNAL OF MEDICAL ECONOMICS

Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

(2010)   AMERICAN HEART JOURNAL

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

(2010) Renato D. Lopes et al.   AMERICAN HEART JOURNAL

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPEAN HEART JOURNAL

Inkrementelle Kosteneffektivität von Dipyridamol + Acetylsalicylsäure in der Sekundärprävention bei ischämischem nichtkardioembolischem Schlaganfall

(2009) Christa Claes et al.   MEDIZINISCHE KLINIK

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of New Anticoagulants: Present and Future

(2009) Job Harenberg   SEMINARS IN THROMBOSIS AND HEMOSTASIS

New Anticoagulants in Atrial Fibrillation

(2009) Job Harenberg   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I

(2009) Joel W. Hay et al.   VALUE IN HEALTH

Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature

(2008) G. Dolan et al.   CURRENT MEDICAL RESEARCH AND OPINION